445 related articles for article (PubMed ID: 31575356)
1. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
Trantham T; Auten J; Muluneh B; Van Deventer H
J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
Yan WL; Yang SL; Zhao FY; Xu XJ
J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
Huang Z; Xie J
Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009
[TBL] [Abstract][Full Text] [Related]
6. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.
Hu S; Bansal P; Lynch D; Rojas Hernandez CM; Dayao Z
J Med Case Rep; 2016 Dec; 10(1):365. PubMed ID: 27998299
[TBL] [Abstract][Full Text] [Related]
7. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C; Nichols KE; Albeituni S
Front Immunol; 2021; 12():614704. PubMed ID: 33664745
[TBL] [Abstract][Full Text] [Related]
8. Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review.
Wang S; Wu J; Jing X; Zhang Y; Tang H; Wu J
Hematology; 2019 Dec; 24(1):751-756. PubMed ID: 33138732
[TBL] [Abstract][Full Text] [Related]
9. [Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review].
Li GM; Jin YB; Gan YZ; Chen C; Jia Y; Li C
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1208-1213. PubMed ID: 36533357
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
Jianguo L; Zhixuan Z; Rong L; Xiaodong S
Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
Sin JH; Zangardi ML
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis.
Chi Y; Liu R; Zhou ZX; Shi XD; Ding YC; Li JG
Pediatr Rheumatol Online J; 2021 Apr; 19(1):49. PubMed ID: 33794928
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
[TBL] [Abstract][Full Text] [Related]
14. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.
Boonstra PS; Ahmed A; Merrill SA; Wilcox RA
Am J Hematol; 2021 Apr; 96(4):E103-E105. PubMed ID: 33428805
[No Abstract] [Full Text] [Related]
17. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
[TBL] [Abstract][Full Text] [Related]
19. A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Malkan UY; Albayrak M; Yildiz A; Maral S; Afacan Ozturk HB; Comert P
J Oncol Pharm Pract; 2021 Jan; 27(1):250-252. PubMed ID: 32507098
[TBL] [Abstract][Full Text] [Related]
20. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
